Sergio Raposeiras-Roubin

List of Publications by Year
in descending order

84 papers	1,279 citations	361413 20 h-index	434195 31 g-index
90 all docs	90 docs citations	90 times ranked	2025 citing authors

#	Article	IF	Citations
1	Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (<scp>DapaTAVI</scp>) randomized trial. European Journal of Heart Failure, 2022, 24, 581-588.	7.1	13
2	Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry. Heart, 2022, 108, 130-136.	2.9	49
3	Incidence and Predictors of Bleeding in Patients With Cancer and Atrial Fibrillation. American Journal of Cardiology, 2022, 167, 139-146.	1.6	4
4	A Score to Assess Mortality After Percutaneous Mitral Valve Repair. Journal of the American College of Cardiology, 2022, 79, 562-573.	2.8	44
5	Nutrition status, obesity and outcomes in patients with atrial fibrillation. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	3
6	Incidence, predictors of bleeding and prognosis of bleeding in anticoagulated nonagenarian patients with atrial fibrillation. International Journal of Cardiology, 2021, 327, 217-222.	1.7	7
7	Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. Circulation: Heart Failure, 2021, 14, e007347.	3.9	17
8	The Art of Prescribing Î²-Blockers After Myocardial Infarction. Circulation: Cardiovascular Interventions, 2021, 14, e010720.	3.9	3
9	Trade-off between the effects of embolic versus bleeding events on mortality in elderly patients with atrial fibrillation. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.6	0
10	Acute myocardial infarction with high Killip class: do geographic differences matter?. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 513-515.	1.0	2
11	Balance entre el efecto de los eventos embÃ³licos frente a los hemorrÃ¡gicos en la mortalidad de los pacientes ancianos con fibrilaciÃ³n auricular. Revista Espanola De Cardiologia, 2021, , .	1.2	0
12	Predictors of Inappropriate Dosing of Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation. Journal of the American Medical Directors Association, 2021, 22, 2395-2397.	2.5	1
13	In-hospital outcomes of mechanical complications in acute myocardial infarction: Analysis from a nationwide Spanish database. Cardiology Journal, 2021, 28, 589-597.	1.2	8
14	Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients with Atrial Fibrillation. Journal of the American Medical Directors Association, 2021, 22, 2190-2195.	2.5	3
15	Safety of digoxin in nonagenarian patients with atrial fibrillation: lessons from the Spanish Multicenter Registry. Journal of Geriatric Cardiology, 2021, 18, 809-815.	0.2	0
16	Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction. Revista Espanola De Cardiologia (English Ed), 2020, 73, 114-122.	0.6	6
17	P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 31-42.	3.0	37
18	Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation. Journal of the American Medical Directors Association, 2020, 21, 367-373.e1.	2.5	18

#	Article	IF	Citations
19	Outcome of Patients With Prior Stroke/Transient Ischemic Attack and Acute Coronary Syndromes. Angiology, 2020, 71, 324-332.	1.8	2
20	New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e016836.	3.7	16
21	Impact of malnutrition in the embolicâ€“haemorrhagic trade-off of elderly patients with atrial fibrillation. Europace, 2020, 22, 878-887.	1.7	22
22	Editorâ€™s Choiceâ€“ Impact of identifying precipitating factors on 30-day mortality in acute heart failure patients. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 667-680.	1.0	15
23	Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor. Thrombosis Research, 2019, 174, 51-58.	1.7	13
24	Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry. American Journal of Cardiovascular Drugs, 2018, 18, 299-309.	2.2	8
25	Prediction of Post-Discharge Bleeding in Elderly Patients with Acute Coronary Syndromes: Insights from the BleeMACS Registry. Thrombosis and Haemostasis, 2018, 118, 929-938.	3.4	19
26	Effect of beta-blocker dose on mortality after acute coronary syndrome. Revista Portuguesa De Cardiologia, 2018, 37, 239-245.	0.5	9
27	Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score. International Journal of Cardiology, 2018, 254, 10-15.	1.7	66
28	Effect of beta-blocker dose on mortality after acute coronary syndrome. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 239-245.	0.2	2
29	Prognostic usefulness of an age-adapted equation for renal function assessment in older patients with acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 703-709.	1.0	3
30	Gender-related differences in post-discharge bleeding among patients with acute coronary syndrome on dual antiplatelet therapy: A BleeMACS sub-study. Thrombosis Research, 2018, 168, 156-163.	1.7	17
31	The Swing of Î²-Blockers. Journal of the American College of Cardiology, 2017, 69, 2721-2724.	2.8	13
32	Tobacco, illicit drugs use and risk of cardiovascular disease in patients living with HIV. Current Opinion in HIV and AIDS, 2017, 12, 523-527.	3.8	22
33	BleeMACS. Journal of Cardiovascular Medicine, 2016, 17, 744-749.	1.5	27
34	CardiopatÃa isquÃ©mica en el VIH: profundizando en el conocimiento del riesgo cardiovascular. Revista Espanola De Cardiologia, 2016, 69, 1204-1213.	1.2	10
35	Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 645-653.	0.2	5
36	NT-proBNP for risk stratification of nonagenarian patients with severe symptomatic aortic stenosis. International Journal of Cardiology, 2016, 223, 785-786.	1.7	2

#	Article	IF	Citations
37	Risk Scores From PARISÂRegistry. Journal of the American College of Cardiology, 2016, 68, 2391-2392.	2.8	0
38	Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. Revista Portuguesa De Cardiologia, 2016, 35, 645-653.	0.5	12
39	Impact of blood transfusion on in-hospital myocardial infarctions according to patterns of acute coronary syndrome: Insights from the BleeMACS registry. International Journal of Cardiology, 2016, 221, 364-370.	1.7	13
40	Ischemic Heart Disease in HIV: An In-depth Look at Cardiovascular Risk. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1204-1213.	0.6	7
41	Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe. International Journal of Cardiology, 2016, 220, 488-495.	1.7	8
42	The Risk of Cardiovascular Events After an Acute Coronary Event Remains High, Especially During the First Year, Despite Revascularization. Revista Espanola De Cardiologia (English Ed), 2016, 69, 11-18.	0.6	27
43	El riesgo de eventos cardiovasculares tras un evento coronario agudo persiste elevado a pesar de la revascularizaciÃ³n, especialmente durante el primer aÃ±o. Revista Espanola De Cardiologia, 2016, 69, 11-18.	1.2	81
44	Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace, 2015, 17, 711-717.	1.7	47
45	Risk stratification for the development of heart failure after acute coronary syndrome at the time of hospital discharge: Predictive ability of GRACE risk score. Journal of Cardiology, 2015, 66, 224-231.	1.9	15
46	Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. BMC Cardiovascular Disorders, 2015, 15, 156.	1.7	20
47	Â¿En la era actual existe beneficio pronÃ³stico del tratamiento con bloqueadores beta tras un sÃndrome coronario agudo con funciÃ³n sistÃ³lica conservada?. Revista Espanola De Cardiologia, 2015, 68, 585-591.	1.2	26
48	Prognostic Benefit of Beta-blockers After Acute Coronary Syndrome With Preserved Systolic Function. Still Relevant Today?. Revista Espanola De Cardiologia (English Ed), 2015, 68, 585-591.	0.6	11
49	Mortality and cardiovascular morbidity within 30 days of discharge following acute coronary syndrome in a contemporary European cohort of patients: How can early risk prediction be improved? The six-month GRACE risk score. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 383-391.	0.2	3
50	Clinical Treatment and Prognosis in Patients With Acute Coronary Syndrome and Anemia. Response. Revista Espanola De Cardiologia (English Ed), 2015, 68, 356.	0.6	0
51	Tratamiento clÃnico y pronÃ³stico en pacientes con sÃndrome coronario agudo y anemia. Respuesta. Revista Espanola De Cardiologia, 2015, 68, 356.	1.2	0
52	Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome. Biomarkers in Medicine, 2015, 9, 209-216.	1.4	8
53	Is safe to discontinue anticoagulation after successful ablation of atrial flutter?. International Journal of Cardiology, 2015, 201, 631-632.	1.7	5
54	Mortality and cardiovascular morbidity within 30 days of discharge following acute coronary syndrome in a contemporary European cohort of patients: How can early risk prediction be improved? The six-month GRACE risk score. Revista Portuguesa De Cardiologia, 2015, 34, 383-391.	0.5	12

#	Article	IF	Citations
55	Relative performance of three formulas to assess renal function at predicting in-hospital hemorrhagic complications in an acute coronary syndrome population. What does the new CKD-EPI formula provide?. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 237-245.	1.0	13
56	Contrast-induced nephropathy and bleeding: A bidirectional link with prognostic value in acute coronary syndrome. International Journal of Cardiology, 2014, 176, 235-236.	1.7	2
57	Usefulness of the QRS-T Angle to Improve Long-Term Risk Stratification of Patients With Acute Myocardial Infarction and Depressed Left Ventricular Ejection Fraction. American Journal of Cardiology, 2014, 113, 1312-1319.	1.6	39
58	Comparative evaluation of HAS-BLED and ATRIA scores by investigating the full potential of their bleeding prediction schemes in non-valvular atrial fibrillation patients on vitamin-K antagonists. International Journal of Cardiology, 2014, 176, 1259-1261.	1.7	9
59	Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. World Journal of Cardiology, 2014, 6, 1140.	1.5	13
60	Discrepancy between stress electrocardiographic changes and nuclear myocardial perfusion defects in the prognostic assessment of patients with chest pain. Revista Portuguesa De Cardiologia, 2013, 32, 761-768.	0.5	4
61	Incidence and prognostic value of infections during an acute coronary syndrome: A single center experience. International Journal of Cardiology, 2013, 168, 1609.	1.7	0
62	Pericarditis seca, diagnÃ³stico con cardiorresonancia magnÃ©tica. Revista Espanola De Cardiologia, 2013, 66, 584.	1.2	2
63	Results of Intra-aortic Balloon Counterpulsation in Patients With ST-elevation Myocardial Infarction With Cardiogenic Shock Undergoing Percutaneous Coronary Intervention: Is There a Benefit?. Revista Espanola De Cardiologia (English Ed), 2013, 66, 590-591.	0.6	0
64	High-sensitivity C-reactive protein predicts adverse outcomes after non-ST-segment elevation acute coronary syndrome regardless of GRACE risk score, but not after ST-segment elevation myocardial infarction. Revista Portuguesa De Cardiologia, 2013, 32, 117-122.	0.5	20
65	Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: Evidence in patients with acute myocardial infarction. European Journal of Pharmaceutical Sciences, 2013, 49, 512-518.	4.0	9
66	Creatinine-or cystatin C-based equations to estimate glomerular filtration rate in acute myocardial infarction: A disparity in estimating renal function and in mortality risk prediction. International Journal of Cardiology, 2013, 168, 4300-4301.	1.7	9
67	Prognostic influence of prior ischemic heart disease in in-hospital mortality of acute coronary syndromes. International Journal of Cardiology, 2013, 168, 5063-5064.	1.7	0
68	A comparison of the CKD-EPI, MDRD-4, and Cockcroftâ€“Gault equations to assess renal function in predicting all-cause mortality in acute coronary syndrome patients. International Journal of Cardiology, 2013, 167, 2325-2326.	1.7	17
69	GRACE Risk Score Predicts Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome and Normal Renal Function. Angiology, 2013, 64, 31-39.	1.8	33
70	Resultados del uso del balÃ³n de contrapulsaciÃ³n en el shock cardiogÃ©nico secundario a infarto agudo de miocardio sometido a revascularizaciÃ³n coronaria percutÃ¡nea: Â¿hay beneficio?. Revista Espanola De Cardiologia, 2013, 66, 590-591.	1.2	3
71	Dosing of iodinated contrast volume: A new simple algorithm to stratify the risk of contrastâ€induced nephropathy in patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2013, 82, 888-897.	1.7	17
72	Current status of NADPH oxidase research in cardiovascular pharmacology. Vascular Health and Risk Management, 2013, 9, 401.	2.3	42

#	Article	IF	Citations
73	Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome. PLoS ONE, 2013, 8, e74302.	2.5	41
74	High-Sensitivity C-Reactive Protein is a Predictor of In-Hospital Cardiac Events in Acute Myocardial Infarction Independently of GRACE Risk Score. Angiology, 2012, 63, 30-34.	1.8	21
75	Evidence for a role of advanced glycation end products in atrial fibrillation. International Journal of Cardiology, 2012, 157, 397-402.	1.7	43
76	Advanced glycation end products: A mysterious shadow beyond the relationship between HbA1c and atrial fibrillation. International Journal of Cardiology, 2012, 157, 441.	1.7	3
77	Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report. Cardiovascular Diabetology, 2012, 11, 102.	6.8	25
78	Is Glycated Hemoglobin an Accurate Enough Predictor of Subclinical Myocardial Injury or a Simple Precursor of Advanced Glycation End Products?. Journal of the American College of Cardiology, 2012, 60, 166-167.	2.8	3
79	Walking Beyond the GRACE (Global Registry of Acute Coronary Events) Model in the Death Risk Stratification During Hospitalization in Patients With Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2012, 5, 1117-1125.	2.9	23
80	Postoperative left ventricular thrombosis and transthoracic echocardiography: is it enough?. Critical Care, 2011, 15, 431.	5.8	0
81	Acute hyperglycemia: Is really a new risk marker for contrast-induced nephropathy in patients with acute myocardial infarction without diabetes and normal renal function?. American Heart Journal, 2011, 162, e7.	2.7	0
82	Relation of Soluble Receptor for Advanced Glycation End Products to Predict Mortality in Patients With Chronic Heart Failure Independently of Seattle Heart Failure Score. American Journal of Cardiology, 2011, 107, 938-944.	1.6	30
83	Letter by Raposeiras-RoubÃn et al Regarding Article, â€œMortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysisâ€: Circulation, 2011, 124, e483; author's reply e484.	1.6	3
84	Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels. European Journal of Heart Failure, 2010, 12, 1092-1100.	7.1	59